Is concomitant quadruple therapy for Helicobacter pylori eradication really needed for Japanese patients? | Zendy

Vincenzo De Francesco | Zendy; Angelo Zullo | Zendy; Cesare Hassan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is concomitant quadruple therapy for Helicobacter pylori eradication really needed for Japanese patients?

Author(s) -

Vincenzo De Francesco,

Angelo Zullo,

Cesare Hassan

Publication year - 2012

Publication title -

world journal of gastrointestinal pharmacology and therapeutics

Language(s) - English

Resource type - Journals

ISSN - 2150-5349

DOI - 10.4292/wjgpt.v3.i6.103

Subject(s) - lansoprazole , clarithromycin , concomitant , metronidazole , amoxicillin , medicine , helicobacter pylori , gastroenterology , pharmacotherapy , surgery , antibiotics , microbiology and biotechnology , biology

The study found that the 7 d of concomitant therapy (lansoprazole, amoxicillin, clarithromycin and metronidazole) achieved significantly higher eradication rates compared to 7 d of triple therapy (lansoprazole, amoxicillin, clarithromycin), the intention to treat (ITT) cure rates being 94.9% and 68.3%, respectively. According to our opinion, this study is clinically relevant for Japanese physicians for at least 2 reasons: (1) the standard triple therapy (clarithromycin plus amoxicillin) achieved disappointing cure rates in Japan - in agreement with what was observed in several countries; and (2) the concomitant quadruple therapy is an effective therapeutic alternative.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research